Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1981 1
1982 2
1984 3
1985 1
1986 1
1987 1
1988 8
1989 2
1990 4
1991 8
1992 10
1993 12
1994 5
1995 9
1996 9
1997 16
1998 8
1999 11
2000 18
2001 25
2002 23
2003 40
2004 55
2005 75
2006 89
2007 86
2008 111
2009 144
2010 146
2011 199
2012 213
2013 251
2014 278
2015 310
2016 401
2017 457
2018 505
2019 602
2020 778
2021 817
2022 362
Text availability
Article attribute
Article type
Publication date

Search Results

5,439 results
Results by year
Filters applied: . Clear all
Page 1
TMBIM1 is an inhibitor of adipogenesis and its depletion promotes adipocyte hyperplasia and improves obesity-related metabolic disease.
Zhao GN, Tian ZW, Tian T, Zhu ZP, Zhao WJ, Tian H, Cheng X, Hu FJ, Hu ML, Tian S, Ding T, Chen S, Ji YX, Zhang P, Zhang XJ, She ZG, Yuan Y, Chen W, Bai L, Li H. Zhao GN, et al. Among authors: tian zw. Cell Metab. 2021 Aug 3;33(8):1640-1654.e8. doi: 10.1016/j.cmet.2021.05.014. Epub 2021 Jun 8. Cell Metab. 2021. PMID: 34107313
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Pan J, et al. Among authors: tian z. J Clin Oncol. 2021 Oct 20;39(30):3340-3351. doi: 10.1200/JCO.21.00389. Epub 2021 Jul 29. J Clin Oncol. 2021. PMID: 34324392 Clinical Trial.
Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Roos FC, Mandel P, Chun FKH, Karakiewicz PI. Wenzel M, et al. Among authors: tian z. Eur Urol Focus. 2021 Apr 11:S2405-4569(21)00109-7. doi: 10.1016/j.euf.2021.04.003. Online ahead of print. Eur Urol Focus. 2021. PMID: 33853754 Review.
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Wenzel M, et al. Among authors: tian z. Prostate Cancer Prostatic Dis. 2021 May 30. doi: 10.1038/s41391-021-00395-4. Online ahead of print. Prostate Cancer Prostatic Dis. 2021. PMID: 34054128 Review.
Advances in NK cell production.
Fang F, Xie S, Chen M, Li Y, Yue J, Ma J, Shu X, He Y, Xiao W, Tian Z. Fang F, et al. Among authors: tian z. Cell Mol Immunol. 2022 Apr;19(4):460-481. doi: 10.1038/s41423-021-00808-3. Epub 2022 Jan 5. Cell Mol Immunol. 2022. PMID: 34983953 Review.
5,439 results